E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Anti-inflammatories against Neurodegenerative Diseases"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (1 November 2018)

Special Issue Editor

Guest Editor
Prof. Dr. Dimitra Hadjipavlou-Litina

Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
Website | E-Mail
Phone: +302310997627
Interests: design; synthesis; biological evaluation; inflammation; cancer; cardiovascular diseases; COX and LOX inhibitors; QSAR

Special Issue Information

Inflammation is implicated in the pathogenesis of a broad spectrum of neurodegenerative diseases. These include Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases, amyotrophic lateral sclerosis, all of the tauopathies, multiple sclerosis and many other less common conditions. The level of inflammation is determined by the concentration and degree of activation of microglial cells while the presence of a spectrum of inflammatory mediators is recorded. Epidemiological studies indicate that anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (NSAIDs), have a sparing effect on AD and PD indicating that inflammation exacerbates the pathology in these diseases. NSAIDs inhibit the generation of nitric oxide radicals and modulate transcription factors which are related to inflammatory reactions including cytokine expression

There are reports suggesting that NSAIDs act independently of cyclooxygenase (COX) inhibition. However classical NSAIDs are still the choice for agents that will slow the progression or delay the onset of AD and other neurodegenerative diseases despite failures of naproxen, celecoxib and rofecoxib in AD clinical trials. Several other classes of anti-inflammatory drugs have been identified as potentially beneficial agents. Thus, combination therapy with other anti-inflammatory agents that work through different mechanisms of action might prove to be beneficial.

Prof. Dr. Dimitra Hadjipavlou-Litina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • neurodegenerative diseases
  • Alzheimer
  • Parkinson
  • Huntington diseases
  • amyotrophic lateral sclerosis
  • tauopathies
  • multiple sclerosis
  • non-steroidal anti-inflammatory drugs
  • drug design
  • drug synthesis
  • biological evaluation
  • cycloxygenase

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to Top